Shih, Ya-Chen Tina http://orcid.org/0000-0001-7290-3864
Xu, Ying
Chien, Chun-Ru
Kim, Bumyang
Shen, Yu
Li, Liang
Geynisman, Daniel M.
Funding for this research was provided by:
National Cancer Institute (R01CA207216, R01 CA225646, R01 CA225646, R01 CA225647, CCSG P30 CA016672)
China Medical University Hospital (CRS-108-054)
Article History
First Online: 8 July 2019
Compliance with Ethical Standards
:
: We acknowledge funding from the China Medical University Hospital (Chien, CRS-108-054) and the National Cancer Institute (Shih, R01 CA207216, R01 CA225646, R01 CA225647 and CCSG P30 CA016672; Li R01 CA225646; Shen Cancer Center Biostatistics Shared Resource CA016672).
: Ying Xu, Bumyang Kim, Yu Shen, and Liang Li have no conflicts of interest (either financial or non-financial) that are directly relevant to the content of this article. Ya-Chen Tina Shih received consulting fees for serving on a review panel for Pfizer Inc; the consulting activity was not related to this study. Chun-Ru Chien received consulting fees and travel support from AstraZeneca; the consulting activities were not related to this study. Daniel M. Geynisman received consulting fees from Genentech and AstraZeneca; none of the consulting activities were related to this study.